Publicaciones en colaboración con investigadores/as de University of Pisa (6)

2024

  1. CLO24-088: Efficacy of Fruquintinib in Less Heavily Pretreated Patients (Pts) With Metastatic Colorectal Cancer (mCRC): Profile-Matched Data From FRESCO and FRESCO-2

    Journal of the National Comprehensive Cancer Network : JNCCN, Vol. 22, Núm. 25

2023

  1. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study

    The Lancet, Vol. 402, Núm. 10395, pp. 41-53

2020

  1. Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials

    Annals of Oncology, Vol. 31, Núm. 1, pp. 88-95

2019

  1. Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study

    Oncologist, Vol. 24, Núm. 2, pp. 185-192

2018

  1. Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Naïve Advanced Pancreatic Neuroendocrine Tumors

    Oncologist, Vol. 23, Núm. 7, pp. 766-e90

2015

  1. Randomized trial of TAS-102 for refractory metastatic colorectal cancer

    New England Journal of Medicine, Vol. 372, Núm. 20, pp. 1909-1919